PTN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Palatin Technologies Inc (PTN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows bullish technical indicators, strong analyst ratings with high price targets, and potential growth in its innovative biotech pipeline. Despite some financial challenges, the company's focus on unmet medical needs and positive sentiment from analysts make it a compelling long-term investment.
The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 59.414, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 19.893, with resistance levels at 23.014 and 24.942.
Strong analyst ratings with high price targets ($50-$
and a focus on innovative biotech solutions.
Positive growth potential in its pipeline, particularly with PL7737 for obesity treatment.
Bullish technical indicators supporting upward price movement.
Financial performance shows a net loss of -7263861 in Q2 2026, despite a significant YoY improvement of 197.40%.
EPS dropped significantly by -51.69% YoY, indicating challenges in profitability.
In Q2 2026, revenue remained flat YoY at 116036. Net income improved significantly by 197.40% YoY but remains negative at -7263861. EPS dropped by -51.69% YoY to -2.86, and gross margin remained stable at 100%.
Analysts are bullish on PTN with multiple Buy ratings and high price targets. Laidlaw initiated coverage with a $60 target, Alliance Global set a $50 target, and both highlighted the company's innovative biotech pipeline. Jefferies lowered the target on a different stock but maintained a Buy rating on PTN.
